相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Identification of human CD4+ T cell populations with distinct antitumor activity
Michelle H. Nelson et al.
SCIENCE ADVANCES (2020)
Inosine is an alternative carbon source for CD8+-T-cell function under glucose restriction
Tingting Wang et al.
NATURE METABOLISM (2020)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4(+) T cells in patients with malignant melanoma
Yoshiko Takeuchi et al.
INTERNATIONAL IMMUNOLOGY (2018)
Emerging biomarkers for cancer immunotherapy in melanoma
Margaret L. Axelrod et al.
SEMINARS IN CANCER BIOLOGY (2018)
Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond
Jeffrey E. Gershenwald et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Carsten Krieg et al.
NATURE MEDICINE (2018)
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Priyanka B. Subrahmanyam et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer
Nataly Manjarrez-Orduno et al.
FRONTIERS IN IMMUNOLOGY (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017
Selma Ugurel et al.
EUROPEAN JOURNAL OF CANCER (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence
Stefanie R. Bailey et al.
NATURE COMMUNICATIONS (2017)
Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
C. Klemann et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2016)
The Prognostic Role of the Preoperative Absolute Lymphocyte Count and Absolute Monocyte Count in Patients With Resected Advanced Melanoma
Nicole M. Rochet et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2015)
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
R. Dummer et al.
ANNALS OF ONCOLOGY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
CD26 Expression on T-Anaplastic Large Cell Lymphoma (ALCL) Line Karpas 299 is associated with increased expression of Versican and MT1-MMP and enhanced adhesion
Pamela A. Havre et al.
BMC CANCER (2013)
Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody
Ryo Hatano et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo
Ivana Z. Matic et al.
BMC IMMUNOLOGY (2012)
CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4+ T effector cells in patients with head and neck squamous cell carcinoma
Magis Mandapathil et al.
ONCOIMMUNOLOGY (2012)
Overcoming immunological tolerance to melanoma: Targeting CTLA-4
F. Stephen Hodi
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2010)
On the origin of serum CD26 and its altered concentration in cancer patients
Oscar J. Cordero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function
Kei Ohnuma et al.
TRENDS IN IMMUNOLOGY (2008)
CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse
R Pacheco et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma:: In vivo persistence, migration, and antitumor effect of transferred T cells
C Yee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
